Bessemer Group
PTCT icon

Bessemer Group’s PTC Therapeutics PTCT Stock Holding History

Bessemer Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.94M Buy
85,056
+32,243
+61% +$2.33M 0.01% 481
2026
Q1 		$3.6M Buy
52,813
+52,572
+21,814% +$3.72M 0.01% 601
2025
Q4 		$18K Buy
241
+68
+39% +$4.94K ﹤0.01% 1925
2025
Q3 		$11K Buy
173
+93
+116% +$4.84K ﹤0.01% 1919
2025
Q2 		$4K Hold
80
– – ﹤0.01% 2084
2025
Q1 		$4K Sell
80
-5
-6% -$250 ﹤0.01% 2107
2024
Q4 		$4K Hold
85
– – ﹤0.01% 2082
2024
Q3 		$3K Buy
+85
New +$2.85K ﹤0.01% 2119
2022
Q2 		– Sell
-107
Closed -$4K – 1999
2022
Q1 		$4K Hold
107
– – ﹤0.01% 1609
2021
Q4 		$4K Hold
107
– – ﹤0.01% 1671
2021
Q3 		$4K Hold
107
– – ﹤0.01% 1546
2021
Q2 		$5K Hold
107
– – ﹤0.01% 1430
2021
Q1 		$5K Buy
+107
New +$6.35K ﹤0.01% 1398
2018
Q2 		– Sell
-20
Closed -$1K – 1767
2018
Q1 		$1K Buy
+20
New +$507 ﹤0.01% 1655

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Bessemer Group's PTCT Position: Q2 2026 in Review

Bessemer Group increased its PTC Therapeutics (PTCT) stake by 61% in Q2 2026, buying an estimated $2.33M and bringing the position to 85,056 shares worth $6.94M. The position accounts for 0.01% of the portfolio, ranked #481.

Bessemer Group first reported a position in PTCT in Q1 2018 and has held it in 14 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Bessemer Group held 85,056 shares of PTC Therapeutics worth $6.94M as of Q2 2026.
  • Bessemer Group bought 32,243 PTC Therapeutics shares in Q2 2026, an estimated $2.33M.
  • PTC Therapeutics made up 0.01% of Bessemer Group's portfolio in Q2 2026, its #481 holding.
  • Bessemer Group first reported a position in PTC Therapeutics in Q1 2018 and has held it in 14 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.